This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk11: Good morning and welcome to the AGTC financial results conference call for the first quarter of fiscal year 2022. Today's call is being recorded. Before we get started, I would like to remind everyone that during this conference call, AGTC may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress including statements about its ongoing and planned clinical trials and preclinical programs. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic, and other risks described in the risk factor section of AGTC's most recently filed annual report on the Form 10-K, and other periodic reports filed with the SEC. AGTC undertakes no obligation to update any forward-looking statements after the date of this call. For introductions and opening remarks, I'd like to turn the call over to Sue Washer, Chief Executive Officer of AGTC. Please go ahead.
spk08: Good morning, and thank you all for joining us. During our last quarterly call in September, I had the pleasure of introducing John Lieber as our new Chief Financial Officer. Today, I am pleased to introduce Susan Schneider, our new Chief Medical Officer, who brings extensive expertise and a track record of success in ophthalmology drug development, including the approval and launch of Lucentis. Her experience and insights will be invaluable as we work to advance our XLRP and achromatopsia trials towards approval and as we expand our clinical portfolio with the advancement of our two lead preclinical programs towards IND smiling. Both Susan and John join me on today's call. Last week, we welcomed Sarah DeSalvatore as Vice President of Clinical Operations, and we expect that her strategic leadership and contributions to the FDA approval of multiple rare disease therapies further enhances our robust clinical development capabilities. Our ability to attract high-quality talent like Susan, John, and Sarah reflects the great potential of our pipeline and technology, as well as our amazing corporate culture, which is built on a shared commitment to improving patients' lives and values the contributions that each member of our team brings towards achieving that vision. Now turning to our ongoing clinical trials, our XLRP program is our nearest-turn opportunity to bring a potentially transformative therapy to patients living with a disease that today has no treatment options. As many of you are aware, we presented promising data from the ongoing Phase 1-2 trial earlier this year. This includes 12-month data from patients in the two highest dose groups in this trial, demonstrating a 50% response rate among patients who meet the inclusion criteria for the ongoing Skyline and VISTA trials, as well as improvements in visual acuity across a wide range of patients that provide supportive evidence of biological response. Additionally, data from a subset of patients in the high-dose group who are available for analysis at 24 months provide evidence of response durability and continued safety. As a reminder, We believe that our Skyline and VISTA trials will be successful if we are able to demonstrate the same 50% response rate as we did in patients in the ongoing Phase I-II trials that meet the inclusion criteria in assuming that we see a favorable safety profile. In September, our clinical collaborator, Dr. Paul Yang, Assistant Professor of Ophthalmology at the KCI Institute, presented data from a 12-month analysis of macular structure using optical coherence to evaluate patients in the Phase 1-2 XLRP trial. The data, which Susan will review in a few minutes, identify a correlation between macular structure and visual function that supports the treatment effect of our XLRP gene therapy candidates. These data add to the growing body of evidence supporting the industry-leading potential of this product candidate, and further increases our confidence in the possibility for positive results in both the Skyline and VISTA clinical trials. Based on the totality of the data generated to date, improvements in visual sensitivity, improvements in visual acuity, positive patient anecdotes, and Dr. Yang's observations of improvements in macular structure, we believe that our XLRP gene therapy may provide meaningful and durable benefits to patients. We are currently conducting the Skyline Phase I-II expansion trial and the VISTA Phase II-III trial, and we expect that data from both trials will support a potential filing of a Biological Assistance Application, or BLA. We anticipate multiple data readouts from our XLRP clinical trials between now and the end of 2022, which Susan will outline in a moment. Each of these readouts is an opportunity to further demonstrate the potential value of our XLRP product candidate, and we believe that collectively these trials will provide the most robust and differentiated set of data for any XLRP gene therapy currently in clinical development. Now let me turn to our chromatopsia clinical program. The data reported to date support the continued development of our chromatopsia clinical candidates and have also allowed us to identify a maximum tolerated dose in pediatric patients. As previously reported, we are moving forward with the clinical development of the B3 program and are preparing an end of phase two briefing document for submission to the FDA on which we expect their feedback in the first half of 2022. The path forward for our A3 product candidate will be determined after additional pediatric patient and preclinical data are available for evaluation. Before moving to our preclinical pipeline, I also wanted to remind everyone about our collaboration with Bionic Sight in optogenetics. Earlier in 2021, Bionic Sight announced promising initial Phase 1-2 data that showed that treated patients, all of whom are complete or near completely blind, can now see light and motion, and in two cases can detect the direction of motion. Our diversified preclinical pipeline provides multiple opportunities to expand into additional disease areas outside of inherited retinal diseases, including in central nervous system or CNS indications and otology indications, and to address large markets outside of the rare disease space, such as the dry form of age-related macular degeneration or dry AMD. As previously reported, we have prioritized our programs in dry AMD and frontal temporal dementia for the advancement to IND filing and are on track to initiate toxicology and biodistribution studies for both programs in 2022. As part of our strategic collaboration with autonomy, the otology program is moving forward with an IND application expected to be filed in the first half of 2023. Key to our ability to advance our clinical and preclinical candidates as quickly as possible is ensuring access to high-quality, scalable, and high-productivity manufacturing. Our leased, build-to-suit Current Good Manufacturing Process, or CGMP, manufacturing and quality control facility remains on track to become operational in the fourth quarter of 2022. We have already made several key hires to support the design and construction of the building and intend to continue to bring an additional staff to support the validation of the facility in the second half of 2022. Our goal for this custom manufacturing capacity is to enable an expedited BLA filing and commercial launch of our XLRP product candidates subject to FDA approval and support late stage development of our chromatopsia program. Our investment in and commitment to this facility reflects both our confidence in the clinical and commercial potential of our XRP and achromatopsia clinical programs and our commitment to supporting more rapid advancement of our entire product pipeline. Critically, this facility will also provide supply chain redundancy and reduce manufacturing risk. Now, I will turn the call over to Susan, who will provide additional detail on our XRP and achromatopsia clinical programs. Susan?
spk06: Thank you, Sue, for the warm welcome. I'm pleased to join my first call as AGTC's Chief Medical Officer, and I'm excited to have the opportunity to share several positive updates for both of our ongoing clinical programs. As Sue mentioned, Dr. Paul Yang presented promising new data from the ongoing Phase 1-2 XLRP clinical trial at the 14th International Symposium on Retinal Degeneration in September. The data he presented were from an analysis of macular structure in patients 12 months after receiving a single dose of our XLRP product candidate. A hallmark of XLRP is at the ellipsoid zone, or EZ, which is a defined region within the photoreceptor layer of the retina degenerates over time, and is eventually lost. The data Dr. Yang presented shows that intact retinal anatomy at baseline predicts potential for improvement. Of 20 patients evaluated in our XLRP Phase 1-2 clinical trial, 13 had intact baseline retinal anatomy, of which 9, or 69%, had either complete recovery or improvement in EZ at six months. By contrast, the seven patients who had end-stage retinal anatomy, as evidenced by absence of the EZ, showed no structural or functional improvements post-treatment. The data also showed that there was a significant association between improvements in visual sensitivity measured by Maya and improvements in retinal health measured by improvement in EZ in groups four to six. Among these patients, four of six with MYA improvement also had EZ improvement, and there was a statistically significant association between MYA improvement and EZ improvement with a p-value of 0.0212. We believe that these data further support a treatment effect from our XLRP product candidate and continue to differentiate the data set for our product candidate from competitive products in development. As Sue also mentioned, we are actively enrolling and dosing patients in both the Skyline and VISTA trials and expect to report multiple data sets from these trials in 2022, including three-month interim Skyline trial results in the first half of 2022, 24-month trial results from the ongoing Phase 1-2 clinical trial in the third quarter of 2022, 12-month Skyline trial results in the fourth quarter of 2022, and six-month interim VISTA trial results in the fourth quarter of 2022. Our clinical collaborator, Dr. Robert Sisk of Cincinnati Children's Hospital and University of Cincinnati College of Medicine, will also make an encore presentation of the 12-month data from the Phase 1-2 trial at the American Academy of Ophthalmology annual meeting taking place from November 12th to 15th, 2021. We're pleased to have this additional opportunity to help educate the ophthalmology community about the potential potential benefits of our XLRP candidate. With respect to the achromatopsia programs, we recently enrolled six pediatric ACHMB3 patients and five pediatric ACHMA3 patients in higher dose groups 5A and 6A and identified a maximum tolerated dose. As we have previously reported, to address suspected unexpected serious adverse reaction, or SUSAR, safety events in pediatric patients in the highest dose group, systemic and local steroid doses were increased, and patients are being monitored closely. I am pleased to say that the patients are doing well, and our investigators are tapering these patients to lower steroid doses. Importantly, we did not see comparable inflammation in the six pediatric patients across both trials at dose group 5A, nor in any of the adult patients, or lowest group 4 pediatric patients, on which we previously reported, and we plan to continue development of our achromatopsia product candidates. We expect to report interim three-month data for the pediatric patients in both achromatopsia trials before the end of 2021. For the B3 program, we are also developing an end of phase two briefing packet for submission to the FDA and expect to receive feedback from the agency in the first half of 2022. The agency's input will play a foundational role in our plans for advancing the achromatopathy of B3 candidate toward a pivotal trial. Now, I'll turn the call over to John for a review of our financial results.
spk10: Thanks, Susan. For the first quarter of fiscal year 2022, we recorded a net loss of $17.1 million compared to a net loss of $15.4 million for the first quarter of 2021. The increase in net loss was primarily due to an approximate $700,000 increase in research and development expenses, an approximate $700,000 increase in general and administrative expenses, and an approximate $300,000 increase in interest expense. We ended the first quarter of fiscal year 2022 with a strong balance sheet, including total cash and cash equivalents of $90.5 million. We believe these funds will be sufficient to allow us to generate data from our ongoing and planned clinical programs and fund currently planned research and discovery programs into calendar year 2023. That concludes the team's remarks today. Operator, you may now open the line for a question and answer period.
spk11: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for your questions. Our first questions come from the line of Joe Pant-Guinness with HC Wainwright. Please proceed with your questions.
spk01: Hey, everybody. Good morning, and thanks for taking the questions. So first, I just wanted to ask about, or maybe a logistical question about the SUSAR events and the achromatopsia study. Is it safe to assume, sorry, no pun intended, that this is really a function of just the higher concentrations that lead to this in pediatric patients. And, you know, it really is expected.
spk08: Morning, Joe. Thanks for your question. And, yeah, we really do believe that this is a dose effect in very young patients. Remember that these pediatric patients are between the ages of four and eight years old. And we didn't see any of this kind of inflammation in any teenagers, in any of the lower dose, or in any of the adults. So we really believe it's a dose effect in these very young children.
spk01: Got it. That's very helpful. And then more on the macro front, you guys are obviously very, very busy with regard to the build out of your new facility that you say should come online next year. So I was just curious, have you had any issues or additional planning that you've had to embark upon regarding the global supply chain issues?
spk08: That's a very good question because I think overall, Joe, we're all experiencing some level of constraints due to supply chain issues. For that reason, we did take a very proactive stance on the manufacturing facility. And even though we're breaking ground and they're moving dirt around, we've actually already ordered the equipment that we're going to need in the facility. with the idea that if it comes in on time or early, that we can store it in our existing facility before we move it in there. So we're really trying to do a ton of advanced planning to make sure that we hit our mark of the engineering runs in late 2022.
spk01: Got it. And my last question, if you don't mind, and thanks for indulging me. I don't know if it's too early to ask this question, but are you willing to take any broader strokes with regard to the design of your future dry AMD program and how you might mix endpoints of, you know, drusen, geographic atrophy, and also visual acuity?
spk08: Yeah, I do think, Joe, that it's a bit too early. I can understand the interest there, but we're really right now putting together our package for the pre-IND meeting with the FDA and developing the protocol synopsis with experts. And so I think we would like to wait and comment on that until we have that protocol synopsis complete.
spk01: Totally understood. Thanks a lot for the comments, Sue.
spk08: Have a great day.
spk11: Thank you. Our next questions come from the line of Dagon Ha with Stiefel. Please proceed with your questions.
spk03: Hi, good morning. Thanks for taking our questions and congrats on all the progress. Sue, maybe if I can just go back to the SUSAR question, understanding that it's probably more dose and patient baseline age related. Can you, I guess, maybe talk a little bit about AVTYF and its function, or is this something that's probably going to be more broad to other serotypes of AAV. Is there anything unique about AAV-TYF, or do you think this is going to be applicable to other perhaps ocular gene therapy programs addressing the pediatric population? And then secondly, just with regards to that Dr. Yang data that you guys were just debriefing us on, very interesting, but I guess just thinking about Development forward, I know previously you were thinking about mobility maze from Skyline, trying to draw correlations to the visual function data and making that as a potential regulatory endpoint. I guess, where does EZ come in, given the correlation data that Dr. Diang presented? Have you guys already interacted with the FDA about perhaps using that also as a supportive measure? Thanks.
spk08: Thanks, Dagon, for the questions. I'll take the two-star question. and then probably give you a top line on the SUSAR versus maize and then give Susan an opportunity to weigh in on her thoughts there. As far as the capsid being differences in capsid being potentially more or less inflammatory, we have presented data and I think we've reviewed it publicly in our corporate presentation where we've looked at multiple capsids side by side, and when you dose these multiple capsids side by side, manufactured the same way, titered the same way, purified the same way, we don't see a difference in the inflammatory response. What we see is that despite whatever capsid you have, at certain high doses, you do see an inflammation response that tapers over time and resolves itself, sometimes even without any steroids whatsoever. And so we don't believe that anything we're seeing in the CSAR has anything to do with the specific capsid. There are some capsids, some engineered capsids that you can screen out of libraries and some more off the beaten track, if you want to say capsids that do create a higher inflammatory response. but not among the TYF or AB5 or AB8 or other capsids that we've looked at over time. We don't see that as a causative effect, just total dose. TYF itself, part of how it was engineered is to actually allow it to dwell within the cell itself longer and get into the nucleus in a higher percentage such that the DNA is available to have higher expression of protein. And that's exactly what we see in side-by-side comparisons of our TYF capsids with others is that it does support in non-human primates about twice the expression of the intended protein as other capsids. So now moving on to Dr. Yang's data, we have already written and talked to the FDA about our protocols for Skyline and VISTA. We do intend that visual sensitivity is the primary endpoint with the mobility maze as a secondary endpoint along with visual acuity. We will be collecting the EZ-Line data, and so I'll turn it over to Susan for comments on its usefulness and supportive nature of supporting our product candidates.
spk06: Thank you, Sue. Yeah, for Dr. Yang, the improvements in anatomy are really quite interesting, and we always look for association and alignment with changes in anatomic structure and visual function. So for that sense, the alignment with the functional changes are very important to be both clinically meaningful and hopefully clinically significant in outcomes. And again, this helps us differentiate our product from others. and help us to meet the unmet need in these patients.
spk11: Thank you. Our next questions come from the line of with Wells Fargo. Please proceed with your questions.
spk09: Good morning. Thanks for taking my questions. So first, I have a couple of questions on enrollment. into the Skyline and VISTA trial, mainly not the enrollment status. I know you generally don't provide update into those on an ongoing basis, but what about the cadence and whether you think that cadence can give you confidence for the now first quarter 22 three-month Skyline readout? given that in the past COVID has impacted enrollment? And also, how do you prioritize the enrollment of VISTA and Skyline, given the potential bottleneck of COVID impact? Thank you.
spk08: So, Yann, thank you for the questions, and I hope you are having a good morning. You're right, we don't usually provide exact enrollment statuses and numbers and types of patients. But we did report earlier, as you mentioned, that over the summer we had had a fairly high cancellation rate for screening and initiation of patient visits. And that has largely gone away. We are not having those issues. The sites are seeing patients on a regular basis. We also have fully used our mobile vision centers. I think many of you have heard us talk about the mobile vision center as a way to capture data during the pandemic, and we use that especially for a chromatopsia patient. It's a mobile vision center that travels directly to the patient's home to be able to test data. We now actually have two fully operational mobile vision centers And not only are they doing follow-up visits in certain cases, they're also screening and pre-screening patients for us. And this is something that the patients and the sites are very appreciative of because when the patients actually have to travel to the sites, they already know that they have been pre-screened and have passed much of the inclusion-exclusion criteria. And so the site knows that its time is going to be well spent with these patients. We're very confident that we've worked through those issues in the summer and we're confident in our data guidance that we've provided.
spk09: Great. Thanks for that very helpful update. Also, another question on a competitive landscape front, I think a competitor reported last month data from intravitually administered AAV gene therapy for XLRP. I know the data set is pretty small and early. Could you share your thoughts on that data set and how should we think about the competitive profiling of that gene therapy? Thank you.
spk08: Again, thank you for that question. We do believe that the data presented was limited. We have no insight other than the data that others have seen, and we would think it was way too early to make a statement about that data, and we would wait to see more full from. We do believe that our product with the subretinal delivery really supports higher expression of the protein needed to have an effect in the photoreceptors, And our data is very strong, and as we've talked about, we now see improvements in visual acuity, visual sensitivity, patient anecdotes, clean safety profile, and then now the encouraging data from Dr. Yang.
spk09: Got it. Thank you, Suzanne. That's very helpful. And maybe if I may have one last question, that is for the 12-month data readout update for the ongoing Phase I-II study at AAO. what incremental data will we see compared with the last 12 months data readout? Thank you.
spk08: Dr. Sisk will not be presenting brand new data. It's really, as Susan described, an encore presentation of the data. But what he will be doing is linking the data in a way that hasn't been concentrated on before. really showing the visual sensitivity data in conjunction with Dr. Yang's analysis of the EZ line and also going through some surgical procedures and improvements that have been there. So it's really a way, a capstone presentation to kind of pull together all of the data that's been released over the last 18 months into one consolidated fashion.
spk09: Great. Thank you, Susan.
spk11: Thank you. Our next questions come from the line of Zegba Jalla with Roth Capital Partners. Please proceed with your questions.
spk05: Good morning. Thanks for taking my questions, and congrats on the new hires. I think just two quick ones for me. The first one is just about Dr. Yang's data. I think Susan noted the impact of not being productive of a response or any facts, and so I was just wondering if you have baseline perimetry threshold that you've set is actually going to be able to also capture that same patient population.
spk08: So, Zegba, good morning and happy to have you on the call. And that's a good question because we've previously talked about how we altered the inclusion-exclusion criteria between the Phase 1-2 and the Skyline and VISTA. And I can say that we were already thinking that there was a correlation here between that baseline Maya and what we would want to see in a healthy retina. So Skyline and VISTA already include a look at this imaging, the EZ line, and we do believe that what we have set for Skyline and VISTA will capture the intent and the findings that Dr. Yang had.
spk05: Thanks. And then the last one here is just about the ACM study and the SUSAR, which is wondering beyond, you know, treating those patients with steroids. Are more patients still being enrolled into the study? How do you plan to proceed regarding dose? And, you know, any thoughts on whether or not that CSAR may have impacted or will impact enrollment into the study?
spk08: So we had completed enrollment in B3 of all intended patients. And I think as we noted previously, in A3 there was only one more patient intended to be enrolled in that very high dose in the young age group. And we have held off on that. We are not dosing that final patient in that very high dose. We think it's prudent to collect long-term data and make sure those patients are doing well and don't have plans at this time to dose that last patient.
spk04: Thanks.
spk11: Thank you. Our next question has come from the line of Matthew Lucchini with BMO Capital Markets. Please proceed with your questions.
spk07: Hi, good morning. Thank you so much for taking the question. Maybe just to start, too, with a bigger picture question. Wanted to ask about the recently announced BCTG, the Bespoke Gene Therapy Consortium, focused on, among other things, AAV. Just wanted to get your perspective on that effort and try to understand how AGTC may be able to leverage whatever findings are eventually resolved from that group. And then secondarily, and more specifically to the company, wanted to ask, following the RSO data, the presentation of XLRP data at RSO, one of the larger meetings where this data has been presented, I was just curious if you could provide Any anecdotal physician feedback you may have gotten at the meeting. And then lastly, on a chromatopsia, just housekeeping, wanted to confirm if any of the SUSAR patients are now fully off of steroids. Thank you very much.
spk08: As far as the VCGP, we think that this is an excellent program that has been started and we are very much engaged in participating and in learning what they bring forward and will definitely think that sharing at some level of information and data around gene therapy treatments is positive for everyone in the industry. And so we'll be watching that very carefully. As far as physician feedback, we've had very positive physician feedback on our XLRP program. And as I have mentioned before, going from Skyline and into VISTA, we're expanding the number of sites dramatically. and really have not had an issue with physicians being interested in becoming sites, in going through the surgical training, and really expanding our reach across the country and into the EU based on the data that we have seen so far. So very positive physician feedback there. And on the SUSARs in the chromatopsia patients, as Susan noted, All of those patients are tapering off steroids, but none of them are completely to zero yet. It hasn't been a long enough period of time to get down to baseline.
spk07: Okay, thanks for taking the time.
spk11: Thank you. As a reminder, if you would like to ask a question, please press star 1 on your telephone keypad. Our next questions come from the line of Kristin Kleska with Cantor Fitzgerald. Please proceed with your questions.
spk04: Hi, good morning, everybody. Thanks for taking my question. Just a quick one here. As you really had the first back-to-back six-month data in January last year, literally right before the pandemic, I wanted to ask how these in-person medical meetings that are taking place, including AAO, are really going to be helpful in terms of you getting the word out, especially because you haven't had too many in-person opportunities since, you know, this initial data as well as the follow-on updates have been presented.
spk08: Thank you for the question, Kristin. I do believe that as meetings return to a more normal cadence and we have more opportunity to interact with people more broadly, that that will be generally helpful. But as I stated, we've been very effective reaching out to physicians and educating them through our key opinion leaders. And we've really dramatically expanded, as I mentioned, the number of sites that are involved in the trial and referring to the trials. So while I think initially there was some lag and concern about getting the word out, I think that that has really, we've been able to be very effective later during the pandemic time. But you're certainly right. I mean, I went to my first large conference a couple of months ago, and it really reminded me how well you can do interacting with people, really getting at their questions, really providing good feedback when you're face-to-face. So we're looking forward to AAO. We're very much looking forward to ARVO and ASGCT in the first half of 2022. And we do think that this will increase our ability to get the word out on our programs.
spk04: Thank you. And then just in light of this recent data at the International Symposium and really starting to put all of the endpoints together and see some correlation, it seems, which is not necessarily unique to the company, that of course earlier intervention is really what's going to lead to the best potential outcomes. So as you start to think about this and awareness increases, what implementations or factors are you considering right now to make sure that the patients that are out there are really getting diagnosed or tested earlier on where there's potential for greater benefit at that point?
spk08: So as far as getting the word out, Kristen, I think that that's another good point that you're making, not only get the word out to physicians but get the word out to patients. And that's where I think our longstanding commitment to patient advocacy and our partnership with the Foundation Fighting Blindness as well as a wide range of patient advocacy groups really stands us in good stead. And we do a lot of work on education and outreach within this area. The Foundation Fighting Blindness now has a registry called MyRetina where they actually provide services to genotype patients, and we're very supportive of that effort. And I think that this is the way the grassroots connections to the different patient advocacy groups This is how you get the word out and make sure people are genotyped and aware of potential clinical trials and then eventually a potential product.
spk04: Great. Thank you very much.
spk11: Thank you. Our next question has come from the line of Yun Zhang with BTIG. Please proceed with your questions.
spk02: Hi. Good morning. Thank you very much for taking the question. So a follow-up question on the EEZ area. Sorry if I missed it, but did you say that you looked at those patients at six months? And did you look at untreated eyes and how do they compare to treated eyes? And also, did you look at the patient at 12 months and maybe at 24 months? And I have a follow-up question, please.
spk08: Union, thanks for the question. And, you know, the data that Dr. Yang analyzed is really very interesting. He was looking in the presentation given and the data that we're describing at the 12-month time point. And certainly based on what we observed at 12 months, we would be very interested to see how that data matures at the 24-month time point. And Susan, do you have any further comments to add?
spk06: No, as I said, it's important to have an alignment with what is functional changes as well as the structural changes. I think some of these, and there was a comment made earlier about treating earlier when we have treatments, and I think that that's supported by these data at looking at the baseline retinal anatomy to hopefully predict outcomes, functional outcomes. Very exciting data, and I agree, longer-term data will be very important for us to look at as well.
spk02: Okay. And I remember that Nistar previously reported virtually very little change in terms of structure in XLRP patients, but recently another company reported two patients, but one probably a little over 10% decrease, and the other one probably around 25% decrease from baseline in untreated eyes. So it seems to be a lot of interpatient variability, and is that mainly due to baseline disease severity, or anything else can contribute to the variability in EZ area, please?
spk08: That's another good question. I can't comment in detail on the data that you're mentioning from NISTAR, which was a program picked up by Biogen. But I can say that XLRP is heterogeneous in its patients, and it can sometimes be very age-related, depending on what age of the patient is compared to the age of another patient. But all of these patients do have a steady decline in the health of their macula as it's being measured, in our case, by the EZ line. So it's not surprising that untreated eyes do decline over time. It's very well documented that that's what happens in these patients. And that's why we're so committed to bringing a product forward because without treatment, All of these patients are going to go blind. That's what the natural history study says. That's what all these patients expect.
spk02: Okay. And last question. On the briefing document for the B3 program of chromatopsia, any changes in terms of what efficacy endpoints you would like to propose to the FDA? Okay.
spk08: No, we're still putting that briefing package together. And like my comments about the protocol for the dry AMD, I think until we have that briefing package put together and have received feedback from the FDA, we'll withhold comments. But as we did with XLRP, we will fully report our interactions with the FDA and the agreed upon protocol.
spk02: Okay, great. Thank you very much.
spk11: Thank you. There are no further questions at this time. I would like to turn the call back over to Sue Washer for any closing comments.
spk08: Thank you. Our first quarter of fiscal 22 reflected continued execution of our clinical trial strategies for our XLRP and achromatopsia gene therapy candidates. We are generating robust clinical and patient-reported data that we believe will support the submission of a BLA for our industry-leading XLRP product candidate and will also enable us to engage in productive discussions with the FDA with regards to the next steps in our Achromatopsia B3 program. We are proud of the quality, quantity, and diversity of data that we have shared with the medical, scientific, patient, and investor communities for our XLRP and Achromatopsia programs And we are excited about the potential for each of these products to transform patient care because we're committed to pursuing visionary science to advance the quality of care for our patients. Our investment in our new leased manufacturing and quality control facility are a key part of our strategy to advance the development of both XLRP and achromatopsia programs as rapidly as possible towards potential approval and commercialization. We know that patients with these diseases have waited their whole lives for a therapy that could make a meaningful difference, and we're committed to addressing this urgent need. With the addition of John, Susan, and Sarah, our team has never been better positioned to prepare for the multiple opportunities that lie ahead. The substantial progress we have made in our clinical programs would not be possible without the continued support of our clinical partners and our investors, and most importantly, without the continued faith of the patients who believe in our technology and our commitment to their cause. I thank all of them, and I look forward to sharing our progress with them and with you in the months ahead.
spk11: Thank you. That does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Have a great day.
Disclaimer